Erasca Inc (ERAS)

Currency in USD
13.925
-0.725(-4.95%)
Real-time Data·
ERAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.78015.530
52 wk Range
1.01016.405
Key Statistics
Prev. Close
14.65
Open
15.31
Day's Range
13.78-15.53
52 wk Range
1.01-16.405
Volume
3.52M
Average Volume (3m)
5.76M
1-Year Change
848.2993%
Book Value / Share
1.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ERAS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.800
Upside
+6.28%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Erasca Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Compare ERAS to Peers and Sector

Metrics to compare
ERAS
Peers
Sector
Relationship
P/E Ratio
−34.2x−4.0x−0.5x
PEG Ratio
−0.82−0.100.00
Price/Book
12.6x3.1x2.6x
Price / LTM Sales
-65.5x3.2x
Upside (Analyst Target)
12.9%70.2%53.2%
Fair Value Upside
Unlock18.3%7.6%Unlock

Analyst Ratings

8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14.800
(+6.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy18.00+28.39%11.00MaintainMar 13, 2026
Stifel
Buy20.00+42.65%-MaintainMar 13, 2026
H.C. Wainwright
Buy20.00+42.65%15.00MaintainMar 13, 2026
Mizuho
Buy19.00+35.52%16.00MaintainMar 13, 2026
Stifel
Buy20.00+42.65%10.00MaintainMar 10, 2026

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
-0.10 / -0.109
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ERAS Income Statement

FAQ

What Is the Erasca (ERAS) Stock Price Today?

The Erasca stock price today is 13,925 USD.

What Stock Exchange Does Erasca Trade On?

Erasca is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Erasca?

The stock symbol for Erasca is "ERAS."

What Is the Erasca Market Cap?

As of today, Erasca market cap is 4,340B USD.

What Is Erasca's Earnings Per Share (TTM)?

The Erasca EPS (TTM) is -0,451.

When Is the Next Erasca Earnings Date?

Erasca will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is ERAS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Erasca Stock Split?

Erasca has split 0 times.

How Many Employees Does Erasca Have?

Erasca has 103 employees.

What is the current trading status of Erasca (ERAS)?

As of Mar 13, 2026, Erasca (ERAS) is trading at a price of 13,925 USD, with a previous close of 14,650 USD. The stock has fluctuated within a day range of 13,780 USD to 15,530 USD, while its 52-week range spans from 1,010 USD to 16,405 USD.

What Is Erasca (ERAS) Price Target According to Analysts?

The average 12-month price target for Erasca is 14,800 USD, with a high estimate of 24 USD and a low estimate of 2 USD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +6,28% Upside potential.

What Is the ERAS Premarket Price?

ERAS's last pre-market stock price is 15,190 USD. The pre-market share volume is 7 960,000, and the stock has decreased by 0,540, or 3,690%.

What Is the ERAS After Hours Price?

ERAS's last after hours stock price is 14,972 USD, the stock has decreased by 0,322, or 2,190%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.